Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors

Digestive Diseases and Sciences

Volumn 34, Issue 3 Supplement, 1989, Pages

  Maton, Paul N ^a   Gardner, Jerry D ^a   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

islet cell tumors; pancreas; SMS 201 995; somatostatin

Indexed keywords

OCTREOTIDE; SOMATOSTATIN;

GASTRINOMA; GLUCAGONOMA; HEARTBURN; HUMAN; HYPERGLYCEMIA; INJECTION PAIN; INSULINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; STEATORRHEA; VIPOMA;

ADENOMA, ISLET CELL; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; OCTREOTIDE; PANCREATIC NEOPLASMS; VIPOMA;

EID: 0024508014     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/BF01536043     Document Type: Article

References (101)

1. Miscellaneous tumors of the pancreas
2. Tumors of the endocrine pancreas
3. The incidence and etiology of Cushing's syndrome in Zollinger-Ellison syndrome
4. Gastrinoma
5. Insulinoma
6. Neuroendocrine tumors: A European view
7. The nonsurgical management of metastatic endocrine tumours to the liver
8. Somatostatin suppresses secretin and pancreatic exocrine secretion
9. Somatostatin: hypothalamic inhibitor of the endocrine pancreas
10. Inhibition of gastrin and gastric acid secretion by growth hormone release inhibiting hormone
11. Inhibition of cholecystokinin-pancreozymin release by somatostatin
12. Somatostatin
13. Suppression of pancreatic endocrine tumour secretion of long-acting somatostatin analogue
14. Investigation of a recurrent VIPoma
15. Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera
16. The effect of somatostatin analogs on secretion of growth, pancreatic and gastrointestinal hormones in man
17. Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet-cell carcinoma
18. Somatostatin and insulinoma
19. Functional and morphologic characterization of human insulinomas
20. Effect of somatostatin on basal and glucose-induced insulin release in five patients with hyperinsulinaemia
21. Responses of patients with insulinomas to stimulators and inhibitors of insulin release that have been linked with cyclic adenosine monophosphate
22. Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome
23. Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusion
24. Use of somatostatin and somatostatin analogs in a patient with a glucagonoma
25. Effect of somatostatin in necrolytic migratory erythema of glucagonoma
26. Metabolic clearance and plasma half-disappearance of exogenous somatostatin in man
27. Glucagonomas, VIPomas, and somatostatinomas
28. Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man
29. SMS 201-995: A very potent and selective octapeptide of somatostatin with prolonged actions
30. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin
31. Pharmacokinetics of SMS 201-995 in healthy subjects
32. Long-term treatment of a vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases
33. Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide responses
34. Neuroendocrine tumours of the gut: Long-term therapy with the somatostatin analogue SMS 201-995
35. Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumours with long-acting somatostatin analogue
36. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera
37. Successful therapy of pancreatic cholera with the long-acting somatostatin analogue SMS 201-995. Relation between plasma concentrations of drug and clinical and biochemical responses
38. Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea
39. The effect of somatostatin analogue SMS 201-995 on fluid and electrolyte transport in a patient with secretory diarrhoea
40. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal and water transport
41. VIPoma syndrome: Effect of a synthetic somatostatin analogue
42. Regression of metastatic VIPoma with somatostatin analogue SMS 201-995
43. SMS 201-995 and endocrine tumours
44. Control of watery diarrhoea syndrome in a patient with a vasoactive intestinal polypeptide-secreting tumor, using SMS 201-995 and dexamethasone
45. Treatment of carcinoid syndrome and VIPoma with a long-acting somatostatin analogue (SMS 201-995)
46. Evaluation of SMS 201-995 in gastrointestinal APUDomas
47. Modulation of functional gastrointestinal endocrine tumours by endogenous and exogenous somatostatin
48. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (Sandostatin)
49. Somatostatin analogue (SMS 201-995) in the management of gastroentropancreatic tumors and diarrhea syndromes
50. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VI-Poma
51. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)
52. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide
53. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome
54. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995
55. Somatostatin analogue-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration
56. Short-term effects of the long-acting somatostatin analogue SMS 201-995 in five cases of APUDoma (four with metastases) and in one case of systemic mastocytosis
57. Improvement of psoriasis with chronic use of somatostatin (SMS) analogue SMS 201-995
58. Effects of somatostatin (SMS) analogue (201-995) on gastrin-releasing peptide (GRP) and pancreatic polypeptide (PP) during provocative testing in a benign insulinoma
59. Malignant insulinoma: Effects of a somatostatin analog (compound SMS 201-995) on serum glucose growth, and gastroenteropancreatic hormones
60. Controle metabolique d'un insulinime par un agoniste d'action prolongee de la somatostatine
61. The role of long-acting somatostatin analogue (SMS 201-995) in the management of a patient with a benign insulin-secreting adenoma of the pancreas and a postoperative pancreatic fistula
62. Perioperative use of long-acting SMS 201-995 in patients with endocrine tumors of the gastroenteropancreatic axis
63. Treatment of APUDomas with the long-acting somatostatin analogue SMS 201-995. Investigations of therapeutic use and digestive side effects
64. On the use of a new somatostatin analogue in the treatment of hypoglycemia in patients with insulinoma
65. Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man
66. Treatment of relapsing bleeding peptic ulcers with somatostatin analogue SMS 201-995 in a patient with Zollinger-Ellison syndrome
67. Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin
68. Long-term treatment of Zollinger-Ellison syndrome (ZES) with long-acting somatostatin: Efficacy on gastric acid and gastrin secretions
69. Efficacy of long-acting somatostatin analogue (SMS 201-995) in the ulcerogenic syndrome
70. Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison syndrome by long-acting somatostatin (SMS 201-995)
71. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995)
72. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: Implications for the treatment of apudomas
73. Somatostatin analog: Effects of hypergastrinemia and hypercalcitoninemia
74. Regression of liver metastases in patients with gastrin-secreting tumour treated with SMS 201-995
75. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995
76. Human pharmacological effects of SMS 201-995 on gastric secretion
77. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome
78. Long-acting somatostatin analog (SMS 201-995) partly antagonizes the trophic effect due to omperazole in rat gastric mucosa
79. Treatment of metastasizing GRF-producing tumor with a long-acting somatostatin analogue
80. Long-term treatment of a metastasizing GRFoma with a somatostatin analogue (SMS 201-995) in a girl with gigantism
81. Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production
82. Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor
83. The effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers
84. Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly
85. Acute and long-term effects of SMS 201-995 in acromegaly
86. Therapy of acromegaly with SMS 201-995: Long-term studies
87. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones
88. Somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth
89. Short-term administration of the somatostatin analogue SMS 201-995 in patients with carcinoid syndrome
90. Impairment of platelet function of growth-hormone release-inhibiting hormone
91. Somatostatinoma syndrome: Biochemical, morphologic, and clinical features
92. Neuroendocrine disorders of the gastroenteropancreatic system
93. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis